Whitehawk Therapeutics, INC. (WHWK) — SEC Filings

Overview

Whitehawk Therapeutics, INC. (WHWK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Whitehawk Therapeutics, Inc. (WHWK) reported a significant strategic shift and financial turnaround for the nine months ended September 30, 2025. The company posted net income of $2.655 million, a substantial improvement from a net loss of $45.418 million in the same period of 2024. This turnaround

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 2 mixed. The dominant filing sentiment for Whitehawk Therapeutics, INC. is neutral.

Filing Type Overview

Whitehawk Therapeutics, INC. (WHWK) has filed 6 10-Q, 11 8-K, 2 DEF 14A, 1 8-K/A, 2 10-K, 4 DEFA14A, 1 SC 13D/A, 2 SC 13G with the SEC between Mar 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (29)

• Whitehawk Soars to Profit on FYARRO Sale, Pivots to ADC Pipeline — 10-Q · Nov 6, 2025 Risk: high
  Whitehawk Therapeutics, Inc. (WHWK) reported a significant strategic shift and financial turnaround for the nine months ended September 30, 2025. The company po
• Whitehawk Boosts Revenue Amidst High R&D Spend — 10-Q · Aug 7, 2025 Risk: medium
  Whitehawk Therapeutics, Inc. reported product revenue of $10.2 million for the three months ended June 30, 2025, and $19.8 million for the six months ended June
• Whitehawk Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 13, 2025 Risk: low
  Whitehawk Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting on a matter submitted to a vote of security holders on June 11, 2025. The company, formerl
• Whitehawk Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Whitehawk Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Aadi Bioscience, Inc., is in the pharmaceutical
• Whitehawk Therapeutics DEF 14A: Executive Pay & Governance — DEF 14A · Apr 28, 2025 Risk: medium
  Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.) filed its DEF 14A on April 28, 2025, detailing executive compensation and corporate governance mat
• Whitehawk Therapeutics Files 8-K/A Amendment — 8-K/A · Mar 31, 2025 Risk: low
  Whitehawk Therapeutics, Inc. filed an 8-K/A on March 31, 2025, to amend a previous filing. The amendment pertains to Item 9.01, Financial Statements and Exhibit
• 10-K Filing — 10-K · Mar 28, 2025
• Whitehawk Therapeutics Completes Asset Acquisition/Disposition — 8-K · Mar 26, 2025 Risk: medium
  On March 25, 2025, Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc. and Aerpio Pharmaceuticals, Inc.) filed an 8-K report detailing the completion o
• Whitehawk Therapeutics, Inc. (fka Aadi Bioscience) Files 8-K — 8-K · Mar 18, 2025 Risk: medium
  On March 18, 2025, Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.) filed an 8-K report. The filing indicates a change in the company's name and po
• Aadi Bioscience Files 8-K: Material Agreement & Shareholder Vote — 8-K · Mar 4, 2025 Risk: medium
  On February 28, 2025, Aadi Bioscience, Inc. entered into a Material Definitive Agreement. The company also submitted matters to a vote of its security holders a
• Aadi Bioscience Files Proxy Materials — DEFA14A · Feb 19, 2025 Risk: low
  Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 19, 2025. This filing relates to the company's Schedule 14A, which is
• Aadi Bioscience Files Proxy Materials — DEFA14A · Feb 18, 2025 Risk: low
  Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 18, 2025. This filing relates to the company's proxy materials, which
• Aadi Bioscience Files Proxy Materials — DEFA14A · Feb 5, 2025 Risk: low
  Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 5, 2025. This filing relates to the company's Schedule 14A, which is a
• Aadi Bioscience Files Definitive Proxy Statement — DEFA14A · Dec 30, 2024 Risk: low
  Aadi Bioscience, Inc. filed a Definitive Proxy Statement (DEFA14A) on December 30, 2024. This filing is soliciting material under Rule 14a-12, indicating it's n
• Aadi Bioscience Files 8-K: Agreements, Equity Sales, Officer Changes — 8-K · Dec 20, 2024 Risk: medium
  On December 19, 2024, Aadi Bioscience, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The compa
• Aadi Bioscience Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Aadi Bioscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine m
• Desai Amends Aadi Bioscience Stake Filing — SC 13D/A · Oct 1, 2024 Risk: medium
  Neil Desai has amended his Schedule 13D filing for Aadi Bioscience, Inc. on October 1, 2024. The filing indicates a change in the beneficial ownership of the co
• Aadi Bioscience Appoints New Chief Medical Officer — 8-K · Sep 30, 2024 Risk: medium
  On September 26, 2024, Aadi Bioscience, Inc. announced the appointment of Dr. Michael J. Nally as its new Chief Medical Officer. Dr. Nally brings extensive expe
• Aadi Bioscience Appoints New CMO, Elects Director — 8-K · Sep 19, 2024 Risk: medium
  Aadi Bioscience, Inc. announced on September 15, 2024, the appointment of Dr. Rajul Patel as Chief Medical Officer and the election of Ms. Sarah Kelly to its Bo
• SC 13G Filing — SC 13G · Sep 3, 2024
• SC 13G Filing — SC 13G · Aug 28, 2024
• Aadi Bioscience Appoints New CMO, Director — 8-K · Aug 22, 2024 Risk: medium
  Aadi Bioscience, Inc. announced on August 16, 2024, the appointment of Dr. Rajul Patel as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Bo
• Aadi Bioscience to be Acquired for $100M — 8-K · Aug 21, 2024 Risk: medium
  Aadi Bioscience, Inc. reported on August 16, 2024, that it has entered into a definitive agreement to be acquired by Anria Acquisition Corp., a wholly-owned sub
• Aadi Bioscience Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
  Aadi Bioscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of 20
• Aadi Bioscience Files 8-K on Shareholder Vote Matters — 8-K · Jun 12, 2024 Risk: medium
  On June 11, 2024, Aadi Bioscience, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates that the
• Aadi Bioscience Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk:
  Aadi Bioscience, Inc. (WHWK) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Aadi Bioscience reported $0 in revenue for Q1 2024, a decrease from $0
• Aadi Bioscience, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 26, 2024 Risk: low
  Aadi Bioscience, Inc. (WHWK) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Aadi Bioscience, Inc. filed a Definitive Proxy Statement (DEF 14A
• Aadi Bioscience Enters Material Definitive Agreement — 8-K · Apr 4, 2024 Risk: medium
  On April 1, 2024, Aadi Bioscience, Inc. entered into a Material Definitive Agreement. The company, formerly known as Aerpio Pharmaceuticals, Inc. and Zeta Acqui
• Aadi Bioscience, Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 13, 2024 Risk: medium
  Aadi Bioscience, Inc. (WHWK) filed a Annual Report (10-K) with the SEC on March 13, 2024. Aadi Bioscience, Inc. filed its 10-K for the fiscal year ending Decemb

Risk Profile

Risk Assessment: Of WHWK's 25 recent filings, 1 were flagged as high-risk, 17 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Whitehawk Therapeutics, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $7.145M
• Net Income: $2.655M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $162.6M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Lennon
• Delaney
• Giacobello
• Desai
• Neil Desai
• 0001878692
• Dan Koeppen
• Dr. Michael J. Nally
• Dr. Rajul Patel
• Ms. Sarah Kelly
• Ms. Sarah E. Kelly
• Gardner

Industry Context

The biotechnology sector, particularly in oncology, is characterized by intense competition and high R&D costs. Companies are increasingly focusing on targeted therapies like antibody drug conjugates (ADCs) due to their potential for improved efficacy and reduced side effects. Strategic partnerships and licensing agreements are common for accessing novel technologies and advancing drug pipelines.

Top Tags

corporate-governance (6) · biotech (5) · 10-Q (4) · financials (4) · proxy-statement (4) · shareholder-vote (3) · filing-update (2) · acquisition (2) · corporate-event (2) · sec-filing (2)

Executive Compensation

From the most recent DEF 14A filing (Apr 26, 2024):

• Desai — Member
• Delaney — Member
• Giacobello — Member

Key Numbers

• Net income: $2.655M — For the nine months ended September 30, 2025, a significant turnaround from a $45.418M net loss in 2024.
• Gain on sale of business: $87.266M — Primary driver of net income for the nine months ended September 30, 2025, from the FYARRO Divestiture.
• Total revenue: $7.145M — For the nine months ended September 30, 2025, a decrease from $18.744M in 2024 due to the FYARRO divestiture.
• Research and development expenses: $71.942M — For the nine months ended September 30, 2025, a 96% increase from $36.683M in 2024, reflecting new ADC pipeline focus.
• Cash, cash equivalents and short-term investments: $162.6M — As of September 30, 2025, providing liquidity for future operations.
• Cash payment for FYARRO Divestiture: $102.4M — Received from KAKEN INVESTMENTS INC. on March 25, 2025.
• Proceeds from PIPE financing: $100.002M — Boosted cash reserves for the nine months ended September 30, 2025.
• Accumulated deficit: $329.999M — As of September 30, 2025, indicating historical losses despite recent net income.
• Shares of common stock outstanding: 47,128,362 — As of November 4, 2025, an increase from 24,680,708 shares at December 31, 2024, due to private placement.
• Up-front license fee: $38.0M — Paid to WuXi Biologics on April 16, 2025, for ADC Therapies.
• Product Revenue: $19.8M — for the six months ended June 30, 2025, indicating sales growth.
• Research and Development Expense: $30.1M — for the six months ended June 30, 2025, showing significant investment in pipeline.
• General and Administrative Expense: $15.2M — for the six months ended June 30, 2025, reflecting operational overhead.
• Product Sales Allowance: $1.5M — as of June 30, 2025, impacting net revenue recognition.
• SEC File Number: 001-38560 — Identifies the company's filing history with the SEC.

Related Companies

BMY · AADI

Frequently Asked Questions